Eyegenex, an innovative biotechnology company focused on ophthalmology, has been selected to present at the Ophthalmology Innovation Summit (OIS) in San Diego on November 22-23, 2024.
The Ophthalmology Innovation Summit is a premier annual event that brings together entrepreneurs, clinical leaders, pharmaceutical companies, and investors in the ophthalmic industry. The summit, scheduled for November 22-23, 2024, will showcase groundbreaking advancements and foster collaboration among key stakeholders to drive innovation and investments in ophthalmology.
Eyegenex is one of the select companies chosen to present its groundbreaking work in gene and peptide therapeutics for both acute and chronic indications of glaucoma. Dr. Prasad Sunkara, President and CEO of Eyegenex, expressed his gratitude, stating: “We are honored to be selected to present at the prestigious OIS meeting. We are also grateful for the opportunity to share our advancements in gene and peptide therapies for preventing vision loss with the esteemed audience at OIS.”
Contact:
Prasad Sunkara, Ph.D
Eyegenex, Inc
Prasad@eyegenex.com
Visit us on social media:
https://www.linkedin.com/company/eyegenex
www.eyegenex.com
